Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma
More than 50% of human cancers harbor <i>TP53</i> mutations and increased expression of <i>Mouse double minute 2 homolog</i> <i>(MDM2)</i>, which contribute to cancer progression and drug resistance. Renal cell carcinoma (RCC) has an unusually high incidence of wild-type p53, with a mutation rate of...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI AG
2020-06-01
|
| Serie: | Cells |
| Soggetti: | |
| Accesso online: | https://www.mdpi.com/2073-4409/9/6/1475 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|